Completed PHASE1 INTERVENTIONAL 1-arm NCT00544258

Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005

A Phase I, Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005, When Applied as 0.05% PEP005 Topical Gel to a 100 cm2 (5 cm x 20 cm) Contiguous Actinic Keratosis(AK) Treatment Area on the Extensor (Dorsal Aspect) Forearm.

Sponsor: Peplin

Conditions Actinic Keratoses

Interventions PEP005

Updated 5 times since 2017 Last updated: Feb 11, 2015 Started: Oct 31, 2007 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Actinic Keratoses, this trial is completed. The trial is conducted by Peplin and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peplin

Data source: Peplin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Silverton Place, 101 Wickham Terrace, Brisbane, Australia